Literature DB >> 3624408

Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay.

R C Brown, J P Aston, I Weeks, J S Woodhead.   

Abstract

A direct immunoassay for circulating intact human PTH (hPTH) is described. The method relies on the formation of an immune complex of labeled antiamino-terminal PTH antibody, intact hPTH, and solid phase antimidregion PTH antibody. A chemiluminescent aryl acridinium ester is used as label. Serum samples (100 microL) are incubated with labeled antibody, and subsequently the bound fraction is separated by the addition of solid phase antibody. The bound luminescence is quantitated in an automatic luminometer. Luminescence intensity is directly proportional to the amount of intact PTH present in the sample. Only intact PTH was found to react in this system; there was no significant interference from PTH fragments. The assay detection limit of 0.8 pmol/L hPTH-(1-84) allowed detection of intact PTH in the serum of all normal subjects tested. A clear distinction was found between hypercalcemic individuals subsequently proven to have primary hyperparathyroidism and those with malignancies. The assay offers several advantages over previously described PTH immunoassays with regard to specificity, rapidity, and reagent stability. It, thus, provides a valuable means of investigating parathyroid physiology and clinical disorders of extracellular calcium metabolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3624408     DOI: 10.1210/jcem-65-3-407

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  37 in total

Review 1.  Intact parathyroid hormone assays.

Authors:  F C Logue; G H Beastall; W D Fraser; D S O'Reilly
Journal:  BMJ       Date:  1990-01-27

2.  Bone turnover during high dose inhaled corticosteroid treatment.

Authors:  N J Ali; S Capewell; M J Ward
Journal:  Thorax       Date:  1991-03       Impact factor: 9.139

3.  Localization of parathyroid tumors using endoscopic ultrasonography in primary hyperparathyroidism.

Authors:  B Catargi; J M Raymond; V Lafarge-Gense; F Leccia; P Roger; A Tabarin
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 4.  Intraoperative parathyroid hormone monitoring.

Authors:  William B Inabnet
Journal:  World J Surg       Date:  2004-11-04       Impact factor: 3.352

5.  Intraoperative parathyroid hormone estimation: a valuable adjunct to parathyroid surgery.

Authors:  G S Robertson; S J Iqbal; A Bolia; P R Bell; P S Veitch
Journal:  Ann R Coll Surg Engl       Date:  1992-01       Impact factor: 1.891

6.  Effects of parathyroid hormone on delayed renal allograft function.

Authors:  C J Ferguson; J D Williams; A Silver; J S Woodhead; J R Salaman
Journal:  BMJ       Date:  1991-08-03

7.  A randomised study on a new cost-effective algorithm of quick intraoperative intact parathyroid hormone assay in secondary hyperparathyroidism.

Authors:  Marcin Barczyński; Stanisław Cichoń; Aleksander Konturek; Wojciech Cichoń
Journal:  Langenbecks Arch Surg       Date:  2005-02-15       Impact factor: 3.445

Review 8.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

9.  A new approach to parathyroidectomy.

Authors:  G L Irvin; D L Prudhomme; G T Deriso; G Sfakianakis; S K Chandarlapaty
Journal:  Ann Surg       Date:  1994-05       Impact factor: 12.969

10.  A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).

Authors:  M Shiraki; M Fukunaga; K Kushida; H Kishimoto; Y Taketani; H Minaguchi; T Inoue; R Morita; H Morii; K Yamamoto; Y Ohashi; H Orimo
Journal:  Osteoporos Int       Date:  2003-04-10       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.